ontorpacept   Click here for help

GtoPdb Ligand ID: 12036

Synonyms: TTI-621 | TTI621
Compound class: Peptide
Comment: Ontorpacept (TTI-621) is a 345 amino acid fusion protein that consists of the N-terminal V domain of human SIRPα fused to the Fc region of human IgG1 that was designed as an immuno-oncology agent [1]. The SIRPα domain binds to CD47 on cancer cells (to block the CD47-SIRPα anti-phagocytic signal). Inclusion of the IgG1 Fc region enhances phagocytosis of malignant cells via interaction with Fcγ receptors.
Click here for help

Ligand Activity Visualisation Charts

These are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts.

✖

View interactive charts of activity data across species
No information available.
Summary of Clinical Use Click here for help
TTI-621 has advanced to clinical evaluation in haematologic malignancies and solid tumours.
Clinical Trials
Clinical Trial ID Title Type Source Comment References
NCT02890368 Trial of Intratumoral Injections of TTI-621 in Subjects With Relapsed and Refractory Solid Tumors and Mycosis Fungoides Phase 1 Interventional Trillium Therapeutics Inc. 2
NCT05139225 A Study of TTI-622 in Combination With Daratumumab Hyaluronidase-fihj in People With Multiple Myeloma Phase 1 Interventional Memorial Sloan Kettering Cancer Center
NCT02663518 A Trial of TTI-621 for Patients With Hematologic Malignancies and Selected Solid Tumors Phase 1 Interventional Trillium Therapeutics Inc.
NCT04996004 A Trial of TTI-621 in Combination With Doxorubicin in Patients With Leiomyosarcoma Phase 1/Phase 2 Interventional Trillium Therapeutics Inc.